Objective: To describe the clinical and molecular genetic findings in 2 carriers of Duchenne muscular dystrophy (DMD) who exhibited marked hemiatrophy. Duchenne muscular dystrophy is an X-linked disorder in which affected male patients harbor mutations in the dystrophin gene. Female patients with heterozygous mutations may be manifesting carriers.
M

ANIFESTING CARRIERS OF
Duchenne muscular dystrophy (DMD) are heterozygous symptomatic female patients who generally present with a milder phenotype than affected male patients. The phenotypic spectrum of the manifesting carrier is broad, encompassing cramps, myalgia, muscle weakness, dilated cardiomyopathy, and, rarely, progressive proximal weakness. 1 This report describes 2 manifesting carriers of DMD who presented with striking right-sided asymmetrical hemiatrophy in the presence of normal left-sided musculature. We present clinical, genetic, radiologic, and histologic data and suggest that a combination of skewed X-inactivation and somatic mosaicism are the likely underlying mechanisms accounting for this unusual presentation.
Consent was obtained from both patients. Genomic DNA was extracted from leukocytes via a Chemagic Magnetic Separation Module I using the 3-mL Chemagic DNA blood kit special (chemagen Biopolymer-Technologie AG, Baesweiler, Germany) or via a Nucleon BACC3 kit (GE Healthcare, Piscataway, New Jersey). Multiplex ligation-dependent probe amplification (MLPA) analysis using probe sets P034 and P035 (MRC-Holland, Amsterdam, the Netherlands) was performed according to the manufacturer's instructions. Muscle RNA was extracted from frozen muscle biopsy specimens using the RNeasy Fibrous Tissue Mini kit (Qiagen, Düsseldorf, Germany). Muscle DNA was extracted from frozen muscle biopsy specimens using organic extraction. To amplify the exon 10-11 duplication in patient 1, reverse transcriptase-polymerase chain reaction (RT-PCR) amplification was performed, as previously described. 2 Open muscle biopsy specimens were frozen in 2-methyl-butane or isopentane, cooled by liquid nitrogen, and stored at −80°C. Ten-micrometer-thick sections were stained with hematoxylin-eosin, periodic acid-Schiff reagent, oil red O, Congo red, and a modified Gomori stain. Enzyme histochemical analysis with NADH (nicotinamide adenine dinucleotide)-tetrazolium-reductase, and adenosine triphosphatase at pH 4.2 and 4.6 was performed according to standard techniques. For immunohistochemical analysis, the 
REPORT OF CASES
CASE 1
Patient 1 presented at age 50 years with an 18-year history of progressive wasting and weakness in her right arm and right leg. There was no family history of muscular dystrophy. The musculature in the left arm and leg was unaffected as were her facial muscles. She denied any cardiac symptoms.
On examination we found marked wasting of her right arm and leg with weakness proximally (Medical Research Council [MRC] grade 3/5) more than distally ( Figure 1A and B). The biceps, supinator, knee, and ankle reflexes on the right were absent but present on the left side. The left arm and leg were entirely normal on examination. The creatinine kinase level was elevated (1448 U/L; reference range, Ͻ200 U/L). (To convert creatinine kinase to microkatals per liter, multiply by 0.0167.) An echocardiogram showed left ventricular dilatation. A magnetic resonance imaging (MRI) scan of her legs revealed clear right-sided muscle atrophy with fatty replacement compared with the left, which was only slightly infiltrated in the posterior compartment ( Figure 1D ).
Histologic examination of the affected right quadriceps muscle demonstrated reduced staining for dystrophin in scattered fibers (Figure 2A-D) . DNA sequencing of the 79 coding exons of the DMD gene (OMIM 300377) did not identify any point mutations, but MLPA analysis revealed a heterozygous duplication of exons 10 and 11, which is predicted to cause a frame shift ( Figure 3A) . X-inactivation studies from genomic DNA, according to the previously published method, 3 revealed a ratio of 0.88, a result suggestive of nonrandom X-inactivation. However, clearly the inactivation pattern, at least in the lymphocytes, was not completely skewed.
To investigate the effect of this duplication on the patient's dystrophin in muscle messenger RNA (mRNA), RT-PCR analysis was performed using primers located in the coding sequence of exons 9 and 13 of the DMD gene and with primers designed to amplify across the duplication breakpoint at the RNA level. 4 In both cases, no mutant RT-PCR products were detected. Sequence analysis of the patient's dystrophin complementary DNA tran- script showed that she was heterozygous for the exon 53 coding sequencing polymorphism r.7728u→c, which had been previously detected in her genomic DNA.
CASE 2
Patient 2 presented at age 35 years with progressive asymmetrical wasting and weakness of her right arm and leg with exertion-dependent myalgia and cramps but with no cardiac symptoms. Examination revealed wasting and weakness of her right arm ( Figure 1C ) and leg. Her left side was unaffected. Deep tendon reflexes were absent on the right side and normal on the left. The creatinine kinase level was elevated at 958 U/L. An MRI scan of her thighs revealed fatty degeneration of the muscles on the right, while the left side showed slight but clear fatty infiltration of muscles from the posterior compartment ( Figure 1E ). Her echocardiogram showed no abnormalities.
Immunostaining of affected deltoid muscle from the right demonstrated a reduced expression of dystrophin compared with the clinically unaffected left side ( Figures 2E-H) ; this was further confirmed by Western blot analysis, which showed a profound reduction in dystrophin expression in the right deltoid. Patient 2 was the mother of a boy diagnosed with DMD who was found to have a deletion of exons 3 through 13 of the DMD gene ( Figure 3B ). Although, this mutation is predicted to maintain the translation reading frame, it is likely that it has a severe disruptive affect on the function of the F-actin domain of the affected son's truncated dystrophin protein, explaining his DMD phenotype. Genetic analysis of the DMD gene of patient 2 showed that she was a carrier of this mutation ( Figure 3B ). X-inactivation studies on lymphocyte DNA revealed no difference in methylation between the 2 X chromosomes. Cytogenetic analysis revealed a normal karyotype, thus excluding Turner syndrome as a possible cause.
COMMENT
The identification of a pathogenic duplication of DMD exons 10 and 11 in patient 1 and a deletion of exons 3 through 13 in patient 2 are consistent with both patients being manifesting carriers of DMD. Immunohistochemical studies on affected muscle further sup- Ex 11 Ex 12 Ex 13 C P 2 S C P 2 S C P 2 S Figure 3 . Multiplex ligation-dependent probe amplification traces showing peak heights. The red peak is a control peak of known copy number with which the patient's DNA (blue peak) is compared. A, Patient 1 (P1) shows a 50% increase in peak height for exons 10 and 11 compared with the control (C), consistent with a tandem duplication. B, Patient 2 (P2) has a 50% reduction in peak height for exons 11, 12, and 13 compared with the control, indicating that she has only 1 copy of each of these exons. Her affected son (S) had no copies of exons 11 through 13.
